Radon indication registry for the assessment of pain reduction, increase of quality of life and improvement in body functionality throughout low-dose radon hyperthermia therapy

Radon Indication Registry - a multi-centre, hypothesis-generating, explorative, uncontrolled, non-interventional, open registry study for the assessment of pain reduction, increase of quality of life and improvement in functionality throughout low-dose radon hyperthermia therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN67336967

Enrollment

5000

Registered

2021-10-11

Start date

2015-12-09

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-inflammatory, degenerative diseases of the musculoskeletal system: ankylosing spondylitis, rheumatoid arthritis, back pain, osteoarthritis in hip and knee, fibromyalgia syndrome, psoriatic arthritis Musculoskeletal Diseases Ankylosing spondylitis, Rheumatoid arthritis, unspecified, Coxarthrosis [arthrosis of hip], Gonarthrosis [arthrosis of knee], Fibromyalgia

Interventions

There are no direct interventions in this registry study. Patients undergo a 2 to 3-week cure stay in the Gastein valley. At the participating medical centers (Gasteiner Heilstollen, Kurzentrum Bad Ho

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >25, 18, <34 kg/m² 4. Being diagnosed one of the six possible indications (ankylosing spondylitis, rheumatoid arthritis, back pain, osteoarthritis in hip and knee, fibromyalgia syndrome, psoriasis arthritis) 5. Being able to attend any form of radon therapy performed in the Gastein Valley

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular disease/arrhythmia 2. Severe kidney dysfunction/inflammatory kidney participation in the context of an autoimmune disease 3. Acute infections 4. Highly acute attack in chronic polyarthritis 5. Hyperthyroidism 6. Malignancy patients: last accomplished chemotherapy or immune therapy has taken place <1 year ago 7. Pregnancy 8. Alcohol and/or drug abuse 9. Lacking language skills 10. Incapability of filling out a questionnaire

Design outcomes

Primary

Measure	Time frame
Measured at T0 (before cure stay), T1 (discharge), T2 (3 months), T3 (6 months), T4 (9 months): 1. Pain scores for rest and movement measured using NRS (numeric rating scale) 2. Quality of life measured using EQ-5D-5L 3. Indication-specific: 3.1. OA: severity of osteoarthritis of the hip and knee measured using the Lequesne index 3.2. RA: RA disease activity and course measured using the Rheumatoid Arthritis Disease Activity Index (RADAI-5) 3.3. Ankylosing spondylitis: degree of functional limitation measured using the Bath Ankylosing Spondylitis Functional Index (BASFI), disease activity measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 3.5. Back pain: back pain-related functional limitations measured using the Funktionsfragebogen Hannover Rücken (FFb-H-R) 3.6. Fibromyalgia syndrome: fibromyalgia (FM) patient status and progress assessed using the Fibromyalgia Impact Questionnaire (FIQ) 3.7. Psoriatic arthritis: the impact of PsA for the patient assessed using the PsAID 12	—

Measure

Time frame

Measured at T0 (before cure stay), T1 (discharge), T2 (3 months), T3 (6 months), T4 (9 months): 1. Pain scores for rest and movement measured using NRS (numeric rating scale) 2. Quality of life measured using EQ-5D-5L 3. Indication-specific: 3.1. OA: severity of osteoarthritis of the hip and knee measured using the Lequesne index 3.2. RA: RA disease activity and course measured using the Rheumatoid Arthritis Disease Activity Index (RADAI-5) 3.3. Ankylosing spondylitis: degree of functional limitation measured using the Bath Ankylosing Spondylitis Functional Index (BASFI), disease activity measured using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 3.5. Back pain: back pain-related functional limitations measured using the Funktionsfragebogen Hannover Rücken (FFb-H-R) 3.6. Fibromyalgia syndrome: fibromyalgia (FM) patient status and progress assessed using the Fibromyalgia Impact Questionnaire (FIQ) 3.7. Psoriatic arthritis: the impact of PsA for the patient assessed using the PsAID 12

—

Secondary

Measure	Time frame
Reduction of drug intake (e.g. NSAR) measured using the responsible clinician's protocols for each patient before and after cure stay (T0 vs T1)	—

Countries

Austria, Germany

Contacts

Public ContactJulia Fuchs

julia.fuchs@pmu.ac.at+43 (0)662 2420 80511

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026